However, Gaiser et al. [25] observed that intravenous administration of blocking anti-CD200 antibody to MCC xenograft mice revealed specific targeting of the drug to the tumor and thus concluded this treatment may provide a novel immunotherapeutic approach for MCC independent of PD-1/PD-L1 inhibition. Here, CD200 is linked to neoplasm.